<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251393</url>
  </required_header>
  <id_info>
    <org_study_id>ACJC2010</org_study_id>
    <nct_id>NCT01251393</nct_id>
  </id_info>
  <brief_title>Cocaine/Crack and Reduction of Compulsion With Biperiden</brief_title>
  <official_title>Cocaine/Crack Dependence: A Study of the Possible Reduction of Compulsion Under the Use of Biperiden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nacional Conseling of Scientific Development and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Considering the effects of the cholinergic system on the drug reward and self-administration
      mechanisms, acetylcholine (Ach) may play an important role on cocaine dependence process.
      Then the present study aims to evaluate biperiden efficacy (a cholinergic antagonist) in
      attenuate compulsion, one o the main symptoms of the drug dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cocaine consumption affects around 13.4 mi people or 0.3% of the world population between 15
      and 64 years old. The drug dependence has been described by many authors as a dysfunction of
      the brain reward system. Considering the effects of the cholinergic system on the drug reward
      and self-administration mechanisms, acetylcholine (Ach) may play an important role on cocaine
      dependence process. Then the present study aims to evaluate biperiden efficacy (a cholinergic
      antagonist) in attenuate compulsion, one o the main symptoms of the drug dependence. To
      accomplish this purpose 60 cocaine or crack male users between 18 and 50 years old will be
      study. This is a double-blind controlled and randomized placebo study. All the patients will
      be treated with brief intervention therapy (BIT), and half of them will receive biperiden
      (6mg/day) while the other half will receive placebo. The treatment efficacy will be evaluated
      through the comparison between the values obtained on the following measures before and after
      the treatment: Craving scale of Minnesota and Cocaine/crack consumption questionnaire, and
      the presence of the cocaine metabolite (benzoylecgonine) on urine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compulsion</measure>
    <time_frame>3 months</time_frame>
    <description>The patients answered the Minnesota Cocaine Craving Scale (Halikas et al., 1991).
INTENSITY: Evaluation of crack strength by cocaine in the previous week:
0 ---------------------------- -----10
Ranges from 0 to 10 (zero = no craving; 10 intense craving). Using a rule starting from 0, we determine the number that corresponds to the compulsion. The farther from 0 the more intense the compulsion will be.
Frequency of craving onset: How many times a day 0 time/day - check: 0 point
time/day - check: 1 point
times/day - check: 2 points
to 5 times/day - check: 3 points
6 to 10 times/day - check: 4 points 11 to 20 times/day - check: 5 points more than 20 times/day - check: 6 points
Ranges from 0 to 6 points (zero = no craving; 1-2 points: Light; 3-4 points: moderate; 5- 6: intense craving).
The sum of the points of the subscales provides the final score.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Biperiden</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Thirty volunteers will take three pills of Placebo (6mg/day) during two months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biperiden</intervention_name>
    <description>Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.</description>
    <arm_group_label>Biperiden</arm_group_label>
    <other_name>Group psychotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Thirty volunteers will take three pills of Placebo (6mg/day) during two months.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Group psychotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cocaine or crack dependence, according to the DSM-IV criteria (APA, 1994)

        Exclusion Criteria:

          -  Being under treatment with psychoactive drugs

          -  Have been diagnosed for other Psychiatric Disorders

          -  Have dependence diagnosis for other drugs, except for tabacco
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José C F. Galduróz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal de São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UDED - Drug Dependence Unit</name>
      <address>
        <city>São Paulo</city>
        <zip>04024-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>November 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2010</study_first_posted>
  <results_first_submitted>February 12, 2019</results_first_submitted>
  <results_first_submitted_qc>February 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2020</results_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Jose Carlos Fernandes Galduroz MD</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Cocaine</keyword>
  <keyword>crack</keyword>
  <keyword>treatment</keyword>
  <keyword>dependence</keyword>
  <keyword>biperiden</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biperiden</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>55 participants in the placebo group and 56 participants in the biperiden group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Biperiden</title>
          <description>Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
Biperiden: Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
Placebo: Thirty volunteers will take three pills of Placebo (6mg/day) during two months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Biperiden</title>
          <description>55 participants took biperidene for 2 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>55 participants took placebo for 2 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.9" spread="7.6"/>
                    <measurement group_id="B2" value="31.5" spread="6.6"/>
                    <measurement group_id="B3" value="32.2" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Compulsion</title>
        <description>The patients answered the Minnesota Cocaine Craving Scale (Halikas et al., 1991).
INTENSITY: Evaluation of crack strength by cocaine in the previous week:
0 ---------------------------- -----10
Ranges from 0 to 10 (zero = no craving; 10 intense craving). Using a rule starting from 0, we determine the number that corresponds to the compulsion. The farther from 0 the more intense the compulsion will be.
Frequency of craving onset: How many times a day 0 time/day - check: 0 point
time/day - check: 1 point
times/day - check: 2 points
to 5 times/day - check: 3 points
6 to 10 times/day - check: 4 points 11 to 20 times/day - check: 5 points more than 20 times/day - check: 6 points
Ranges from 0 to 6 points (zero = no craving; 1-2 points: Light; 3-4 points: moderate; 5- 6: intense craving).
The sum of the points of the subscales provides the final score.</description>
        <time_frame>3 months</time_frame>
        <population>A total sample of 166 patients was evaluated during the project. Of that number, 55 did not fulfil the inclusion criteria. The main reasons for exclusion were the presence of clinical comorbidities (active hepatitis, tuberculosis under treatment and epilepsy) or psychiatric comorbidities.</population>
        <group_list>
          <group group_id="O1">
            <title>Biperiden</title>
            <description>Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
Biperiden: Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
Placebo: Thirty volunteers will take three pills of Placebo (6mg/day) during two months.</description>
          </group>
        </group_list>
        <measure>
          <title>Compulsion</title>
          <description>The patients answered the Minnesota Cocaine Craving Scale (Halikas et al., 1991).
INTENSITY: Evaluation of crack strength by cocaine in the previous week:
0 ---------------------------- -----10
Ranges from 0 to 10 (zero = no craving; 10 intense craving). Using a rule starting from 0, we determine the number that corresponds to the compulsion. The farther from 0 the more intense the compulsion will be.
Frequency of craving onset: How many times a day 0 time/day - check: 0 point
time/day - check: 1 point
times/day - check: 2 points
to 5 times/day - check: 3 points
6 to 10 times/day - check: 4 points 11 to 20 times/day - check: 5 points more than 20 times/day - check: 6 points
Ranges from 0 to 6 points (zero = no craving; 1-2 points: Light; 3-4 points: moderate; 5- 6: intense craving).
The sum of the points of the subscales provides the final score.</description>
          <population>A total sample of 166 patients was evaluated during the project. Of that number, 55 did not fulfil the inclusion criteria. The main reasons for exclusion were the presence of clinical comorbidities (active hepatitis, tuberculosis under treatment and epilepsy) or psychiatric comorbidities.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="2.6"/>
                    <measurement group_id="O2" value="5.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We evaluated the normality (Kolmogorov's test) and homogeneity (Levene's test) of the sample.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The comparisons between the placebo and the biperiden groups at baseline were performed by means of the independent t-Test. We evaluated the normality (Kolmogorov’s test) and homogeneity (Levene’s test) of the sample.
We used an ANOVA for repeated measures, followed by Bonferroni’s post-hoc test to evaluate the efficacy of biperiden in reducing consumption of cocaine/crack.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>We used an ANOVA for repeated measures, followed by Bonferroni’s post-hoc test to evaluate the efficacy of biperiden in reducing consumption of cocaine/crack.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>No adverse event</description>
        </group>
        <group group_id="E2">
          <title>Biperiden</title>
          <description>No adverse event</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="00" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="00" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="00" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>PhD José Carlos F. Galduróz</name_or_title>
      <organization>Universidade Federal de São Paulo</organization>
      <email>galduroz@unifesp.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

